Home/Pipeline/AYA™ (etonogestrel) contraceptive vaginal system

AYA™ (etonogestrel) contraceptive vaginal system

Contraception

FiledUnder FDA Review

Key Facts

Indication

Contraception

Phase

Filed

Status

Under FDA Review

Company

Organon

About Organon

Organon's mission is to improve the health of women throughout their lives by addressing critical gaps in reproductive health, contraception, fertility, and menopause. The company has achieved immediate global scale with a portfolio in over 140 markets, leveraging its heritage brands and deep commercial expertise. Its strategy focuses on maximizing the value of its established therapeutic portfolio, expanding access to biosimilars, and advancing a targeted pipeline in women's health to drive sustainable growth.

View full company profile

Therapeutic Areas

Women's Health Biosimilars Established Brands (Cardiovascular, Respiratory, Dermatology, CNS, etc.)

Other Contraception Drugs

Drug	Company	Phase	Status
Gen II FemCap Commercialization	FemCap	Approved	Active
Eucontra	Hera Health Solutions	Filed	Active
DARE to PLAN™	Daré Bioscience	Unknown	Active
3Daughters IUD	3Daughters	Pre-clinical	Active
Twirla® (levonorgestrel/ethinyl estradiol)	Agile Therapeutics	Approved	Commercial
Copper 175 mm² IUD	Sebela Pharmaceuticals	Phase 3	Active
Novel Oral Contraceptive Combinations	RPG Life Sciences	Formulation Development	Active